Dietary carbohydrate restriction in the management of NAFLD and metabolic syndrome

Nutrition and Cardiometabolic Health

Volumn , Issue , 2017, Pages 275-296

  Jones, Grace Marie ^a   Mulligan, Kathleen ^a,b   Schwarz, Jean Marc ^a,b  

^a Touro University California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85048301096     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781315119410     Document Type: Chapter

References (158)

1. Adams, L. A., C. O. Zein, P. Angulo, and K. D. Lindor (2004). A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 99(12): 2365-2368.
2. Aguilar-Olivos, N. E., P. Almeda-Valdes, C. A. Aguilar-Salinas, M. Uribe, and N. Mendez-Sanchez (2015). The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism 65(8): 1196-1207.
3. Aller, R., D. A. De Luis, O. Izaola, R. Conde, M. Gonzalez Sagrado, D. Primo, B. De La Fuente, and J. Gonzalez (2011). Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15(9): 1090-1095.
4. Amarapurkar, D., P. Kamani, N. Patel, P. Gupte, P. Kumar, S. Agal, R. Baijal, S. Lala, D. Chaudhary, and A. Deshpande (2007). Prevalence of non-alcoholic fatty liver disease: Population based study. Ann Hepatol 6(3): 161-163.
5. Andersen, T., C. Gluud, M. B. Franzmann, and P. Christoffersen (1991). Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12(2): 224-229.
6. Armstrong, M. J., P. Gaunt, G. P. Aithal, D. Barton, D. Hull, R. Parker, J. M. Hazlehurst et al. (2016). Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019): 679-690.
7. Armstrong, M. J., D. D. Houlihan, L. Bentham, J. C. Shaw, R. Cramb, S. Olliff, P. S. Gill, J. M. Neuberger, R. J. Lilford, and P. N. Newsome (2012). Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 56(1): 234-240.
8. Bae, J. C., S. Suh, S. E. Park, E. J. Rhee, C. Y. Park, K. W. Oh, S. W. Park et al. (2012). Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One 7(10): e46819.
9. Bedogni, G., L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani (2005). Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology 42(1): 44-52.
10. Belfort, R., S. A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas et al. (2006). A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355(22): 2297-2307.
11. Bezerra Duarte, S. M., J. Faintuch, J. T. Stefano, M. B. Sobral de Oliveira, D. F. de Campos Mazo, F. Rabelo, D. Vanni, M. A. Nogueira, F. J. Carrilho, and C. P. Marques Souza de Oliveira (2014). Hypocaloric highprotein diet improves clinical and biochemical markers in patients with nonalcoholic fatty liver disease (NAFLD). Nutr Hosp 29(1): 94-101.
12. Bjermo, H., D. Iggman, J. Kullberg, I. Dahlman, L. Johansson, L. Persson, J. Berglund et al. (2012). Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: A randomized controlled trial. Am J Clin Nutr 95(5): 1003-1012.
13. Bondini, S. and Z. M. Younossi (2006). Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol 52(2): 135-143.
14. Bower, G., T. Toma, L. Harling, L. R. Jiao, E. Efthimiou, A. Darzi, T. Athanasiou, and H. Ashrafian (2015). Bariatric surgery and non-alcoholic fatty liver disease: A systematic review of liver biochemistry and histology. Obes Surg 25(12): 2280-2289.
15. Bozzetto, L., A. Prinster, G. Annuzzi, L. Costagliola, A. Mangione, A. Vitelli, R. Mazzarella et al. (2012). Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 35(7): 1429-1435.
16. Browning, J. D., J. A. Baker, T. Rogers, J. Davis, S. Satapati, and S. C. Burgess (2011). Short-term weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 93(5): 1048-1052.
17. Browning, J. D., L. S. Szczepaniak, R. Dobbins, P. Nuremberg, J. D. Horton, J. C. Cohen, S. M. Grundy, and H. H. Hobbs (2004). Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40(6): 1387-1395.
18. Brunt, E. M. (2015). Nonalcoholic fatty liver disease. Nat Rev Dis Primers 1: 15080.
19. Bugianesi, E., E. Gentilcore, R. Manini, S. Natale, E. Vanni, N. Villanova, E. David, M. Rizzetto, and G. Marchesini (2005). A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100(5): 1082-1090.
20. Caballeria, L., G. Pera, M. A. Auladell, P. Toran, L. Munoz, D. Miranda, A. Aluma et al. (2010). Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 22(1): 24-32.
21. Cani, P. D., J. Amar, M. A. Iglesias, M. Poggi, C. Knauf, D. Bastelica, A. M. Neyrinck et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7): 1761-1772.
22. Cani, P. D. and N. M. Delzenne (2009). Interplay between obesity and associated metabolic disorders: New insights into the gut microbiota. Curr Opin Pharmacol 9(6): 737-743.
23. Caricilli, A. M. and M. J. Saad (2013). The role of gut microbiota on insulin resistance. Nutrients 5(3): 829-851.
24. Cariou, B., K. van Harmelen, D. Duran-Sandoval, T. H. van Dijk, A. Grefhorst, M. Abdelkarim, S. Caron et al. (2006). The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281(16): 11039-11049.
25. Cassol, E., V. Misra, A. Holman, A. Kamat, S. Morgello, and D. Gabuzda (2013). Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 13: 203.
26. Catalan, V., J. Gomez-Ambrosi, A. Rodriguez, B. Ramirez, P. Andrada, F. Rotellar, V. Valenti et al. (2015). Expression of S6K1 in human visceral adipose tissue is upregulated in obesity and related to insulin resistance and inflammation. Acta Diabetol 52(2): 257-266.
27. Centis, E., R. Marzocchi, S. Di Domizio, M. F. Ciaravella, and G. Marchesini (2010). The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis 28(1): 267-273.
28. Chalasani, N., Z. Younossi, J. E. Lavine, A. M. Diehl, E. M. Brunt, K. Cusi, M. Charlton et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142(7): 1592-1609.
29. Charatcharoenwitthaya, P. and K. D. Lindor (2007). Role of radiologic modalities in the management of nonalcoholic steatohepatitis. Clin Liver Dis 11(1): 37-54, viii.
30. Chen, S., X. Zhao, L. Ran, J. Wan, X. Wang, Y. Qin, F. Shu et al. (2015). Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis 47(3): 226-232.
31. Chou, T. C., W. M. Liang, C. B. Wang, T. N. Wu, and L. W. Hang (2015). Obstructive sleep apnea is associated with liver disease: A population-based cohort study. Sleep Med 16(8): 955-960.
32. Das, K., K. Das, P. S. Mukherjee, A. Ghosh, S. Ghosh, A. R. Mridha, T. Dhibar et al. (2010). Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51(5): 1593-1602.
33. Dasarathy, S., J. Dasarathy, A. Khiyami, R. Joseph, R. Lopez, and A. J. McCullough (2009). Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. J Hepatol 51(6): 1061-1067.
34. Dobrzyn, A. and J. M. Ntambi (2005). Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev 6(2): 169-174.
35. Dobrzyn, P., A. Dobrzyn, M. Miyazaki, P. Cohen, E. Asilmaz, D. G. Hardie, J. M. Friedman, and J. M. Ntambi (2004). Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc Natl Acad Sci USA 101(17): 6409-6414.
36. Dongiovanni, P., S. Romeo, and L. Valenti (2015). Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int 2015: 460190.
37. Donnelly, K. L., C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115(5): 1343-1351.
38. Du, J., Y. Y. Ma, C. H. Yu, and Y. M. Li (2014). Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 20(2): 569-577.
39. Duseja, A., A. Das, R. K. Dhiman, Y. K. Chawla, K. T. Thumburu, S. Bhadada, and A. Bhansali (2007). Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 6(4): 222-226.
40. Eguchi, Y., T. Eguchi, T. Mizuta, Y. Ide, T. Yasutake, R. Iwakiri, A. Hisatomi et al. (2006). Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol 41(5): 462-469.
41. Fabbrini, E., S. Sullivan, and S. Klein (2010). Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 51(2): 679-689.
42. Faeh, D., K. Minehira, J. M. Schwarz, R. Periasamy, S. Park, and L. Tappy (2005). Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 54(7): 1907-1913.
43. Faghihzadeh, F., P. Adibi, R. Rafiei, and A. Hekmatdoost (2014). Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 34(10): 837-843.
44. Greenhill, C. (2015). Obesity: Gut microbiota, host genetics and diet interact to affect the risk of developing obesity and the metabolic syndrome. Nat Rev Endocrinol 11(11): 630.
45. Guaraldi, G., N. Squillace, C. Stentarelli, G. Orlando, R. D’Amico, G. Ligabue, F. Fiocchi et al. (2008). Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: Prevalence, characteristics, and predictors. Clin Infect Dis 47(2): 250-257.
46. Gugliucci, A., R. H. Lustig, R. Caccavello, A. Erkin-Cakmak, S. M. Noworolski, V. W. Tai, M. J. Wen, K. Mulligan, and J. M. Schwarz (2016). Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis 253: 171-177.
47. Haufe, S., S. Engeli, P. Kast, J. Bohnke, W. Utz, V. Haas, M. Hermsdorf et al. (2011). Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 53(5): 1504-1514.
48. Haukeland, J. W., Z. Konopski, H. B. Eggesbo, H. L. von Volkmann, G. Raschpichler, K. Bjoro, T. Haaland, E. M. Loberg, and K. Birkeland (2009). Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol 44(7): 853-860.
49. Hazlehurst, J. M. and J. W. Tomlinson (2013). Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol 169(2): R27-R37.
50. Higuchi, N., M. Kato, Y. Shundo, H. Tajiri, M. Tanaka, N. Yamashita, M. Kohjima et al. (2008). Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res 38(11): 1122-1129.
51. Holmen, O. L., H. Zhang, Y. Fan, D. H. Hovelson, E. M. Schmidt, W. Zhou, Y. Guo et al. (2014). Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 46(4): 345-351.
52. Hsiao, P. J., K. K. Kuo, S. J. Shin, Y. H. Yang, W. Y. Lin, J. F. Yang, C. C. Chiu, W. L. Chuang, T. R. Tsai, and M. L. Yu (2007). Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 22(12): 2118-2123.
53. Hu, T., K. T. Mills, L. Yao, K. Demanelis, M. Eloustaz, W. S. Yancy, Jr., T. N. Kelly, J. He, and L. A. Bazzano (2012). Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: A meta-analysis of randomized controlled clinical trials. Am J Epidemiol 176 (Suppl 7): S44-S54.
54. Huang, M. A., J. K. Greenson, C. Chao, L. Anderson, D. Peterman, J. Jacobson, D. Emick, A. S. Lok, and H. S. Conjeevaram (2005). One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study. Am J Gastroenterol 100(5): 1072-1081.
55. Ji, H. F., Y. Sun, and L. Shen (2014). Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: Results from a meta-analysis. Nutrition 30(9): 986-991.
56. Jung, C. H., J. E. Jang, and J. Y. Park (2014). A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor. Diabetes Metab J 38(4): 261-273.
57. Kang, H., J. K. Greenson, J. T. Omo, C. Chao, D. Peterman, L. Anderson, L. Foess-Wood, M. A. Sherbondy, and H. S. Conjeevaram (2006). Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 101(10): 2247-2253.
58. Kani, A. H., S. M. Alavian, A. Esmaillzadeh, P. Adibi, and L. Azadbakht (2014). Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: A parallel randomized trial. Nutrition 30(7-8): 814-821.
59. Karoli, R., J. Fatima, A. Chandra, U. Gupta, F. U. Islam, and G. Singh (2013). Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci 6(1): 9-14.
60. Kirpich, I. A., L. S. Marsano, and C. J. McClain (2015). Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem 48(13-14): 923-930.
61. Kitamoto, A., T. Kitamoto, T. Nakamura, Y. Ogawa, M. Yoneda, H. Hyogo, H. Ochi et al. (2014). Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J 61(7): 683-689.
62. Kleiner, D. E., E. M. Brunt, M. Van Natta, C. Behling, M. J. Contos, O. W. Cummings, L. D. Ferrell et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6): 1313-1321.
63. Kozlitina, J., E. Smagris, S. Stender, B. G. Nordestgaard, H. H. Zhou, A. Tybjaerg-Hansen, T. F. Vogt, H. H. Hobbs, and J. C. Cohen (2014). Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46(4): 352-356.
64. Krebs, J. D., C. R. Elley, A. Parry-Strong, H. Lunt, P. L. Drury, D. A. Bell, E. Robinson, S. A. Moyes, and J. I. Mann (2012). The Diabetes Excess Weight Loss (DEWL) Trial: A randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes. Diabetologia 55(4): 905-914.
65. Lambert, J. E., J. A. Parnell, B. Eksteen, M. Raman, M. R. Bomhof, K. P. Rioux, K. L. Madsen, and R. A. Reimer (2015). Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: A randomized controlled trial protocol. BMC Gastroenterol 15: 169.
66. Lambert, J. E., M. A. Ramos-Roman, J. D. Browning, and E. J. Parks (2014). Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146(3): 726-735.
67. Lavine, J. E., J. B. Schwimmer, M. L. Van Natta, J. P. Molleston, K. F. Murray, P. Rosenthal, S. H. Abrams et al. (2011). Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 305(16): 1659-1668.
68. Lee, J. Y., K. M. Kim, S. G. Lee, E. Yu, Y. S. Lim, H. C. Lee, Y. H. Chung, Y. S. Lee, and D. J. Suh (2007). Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. J Hepatol 47(2): 239-244.
69. Lewis, G. F., K. D. Uffelman, L. W. Szeto, B. Weller, and G. Steiner (1995). Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95(1): 158-166.
70. Ley, R. E., P. J. Turnbaugh, S. Klein, and J. I. Gordon (2006). Microbial ecology: Human gut microbes associated with obesity. Nature 444(7122): 1022-1023.
71. Li, C. L., L. J. Zhao, X. L. Zhou, H. X. Wu, and J. J. Zhao (2015). Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease. J Huazhong Univ Sci Technolog Med Sci 35(3): 333-336.
72. Lima-Cabello, E., M. V. Garcia-Mediavilla, M. E. Miquilena-Colina, J. Vargas-Castrillon, T. Lozano-Rodriguez, M. Fernandez-Bermejo, J. L. Olcoz, J. Gonzalez-Gallego, C. Garcia-Monzon, and S. Sanchez-Campos (2011). Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci (Lond) 120(6): 239-250.
73. Liu, Q., S. Bengmark, and S. Qu (2010). The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis 9: 42.
74. Lo, J. C., K. Mulligan, M. A. Noor, J. M. Schwarz, R. A. Halvorsen, C. Grunfeld, and M. Schambelan (2001). The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86(8): 3480-3487.
75. Loomba, R., G. Lutchman, D. E. Kleiner, M. Ricks, J. J. Feld, B. B. Borg, A. Modi et al. (2009). Clinical trial: Pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 29(2): 172-182.
76. Ludwig, J., T. R. Viggiano, D. B. McGill, and B. J. Oh (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55(7): 434-438.
77. Ludwig, U., D. Holzner, C. Denzer, A. Greinert, M. M. Haenle, S. Oeztuerk, W. Koenig et al. (2015). Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: A cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocr Disord 15(1): 41.
78. Lustig, R. H., K. Mulligan, S. M. Noworolski, V. W. Tai, M. J. Wen, A. Erkin-Cakmak, A. Gugliucci, and J. M. Schwarz (2016). Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity (Silver Spring) 24(2): 453-460.
79. Machado, M. V. and H. Cortez-Pinto (2012). Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 11(4): 440-449.
80. Mahdessian, H., A. Taxiarchis, S. Popov, A. Silveira, A. Franco-Cereceda, A. Hamsten, P. Eriksson, and F. van’t Hooft (2014). TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA 111(24): 8913-8918.
81. Makkonen, J., K. H. Pietilainen, A. Rissanen, J. Kaprio, and H. Yki-Jarvinen (2009). Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: A study in monozygotic and dizygotic twins. J Hepatol 50(5): 1035-1042.
82. Marchesini, G., M. Brizi, G. Bianchi, S. Tomassetti, M. Zoli, and N. Melchionda (2001). Metformin in nonalcoholic steatohepatitis. Lancet 358(9285): 893-894.
83. Masters, B., S. Aarabi, F. Sidhwa, and F. Wood (2012). High-carbohydrate, high-protein, low-fat versus lowcarbohydrate, high-protein, high-fat enteral feeds for burns. Cochrane Database Syst Rev 1: CD006122.
84. Masuoka, H. C. and N. Chalasani (2013). Nonalcoholic fatty liver disease: An emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 1281: 106-122.
85. Maximos, M., F. Bril, P. Portillo Sanchez, R. Lomonaco, B. Orsak, D. Biernacki, A. Suman, M. Weber, and K. Cusi (2015). The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 61(1): 153-160.
86. Mayes, P. A. and M. E. Laker (1986). Effects of acute and long-term fructose administration on liver lipid metabolism. Prog Biochem Pharmacol 21: 33-58.
87. Miele, L., V. Valenza, G. La Torre, M. Montalto, G. Cammarota, R. Ricci, R. Masciana et al. (2009). Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49(6): 1877-1887.
88. Mittendorfer, B., F. Magkos, E. Fabbrini, B. S. Mohammed, and S. Klein (2009). Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity (Silver Spring) 17(10): 1872-1877.
89. Miyazaki, Y., A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, L. J. Mandarino, and R. A. DeFronzo (2002). Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87(6): 2784-2791.
90. Mohan, V., S. Farooq, M. Deepa, R. Ravikumar, and C. S. Pitchumoni (2009). Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 84(1): 84-91.
91. Moscatiello, S., R. Di Luzio, E. Bugianesi, A. Suppini, I. J. Hickman, S. Di Domizio, R. Dalle Grave, and G. Marchesini (2011). Cognitive-behavioral treatment of nonalcoholic Fatty liver disease: A propensity score-adjusted observational study. Obesity (Silver Spring) 19(4): 763-770.
92. Mouzaki, M., E. M. Comelli, B. M. Arendt, J. Bonengel, S. K. Fung, S. E. Fischer, I. D. McGilvray, and J. P. Allard (2013). Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58(1): 120-127.
93. Nadeau, K. J., L. B. Ehlers, P. S. Zeitler, and K. Love-Osborne (2009). Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes 10(1): 5-13.
94. Nair, S., A. M. Diehl, M. Wiseman, G. H. Farr, Jr., and R. P. Perrillo (2004). Metformin in the treatment of nonalcoholic steatohepatitis: A pilot open label trial. Aliment Pharmacol Ther 20(1): 23-28.
95. Nalbantoglu, I. L. and E. M. Brunt (2014). Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol 20(27): 9026-9037.
96. Neuschwander-Tetri, B. A., R. Loomba, A. J. Sanyal, J. E. Lavine, M. L. Van Natta, M. F. Abdelmalek, N. Chalasani et al. (2015). Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 385(9972): 956-965.
97. Nobili, V., N. Alkhouri, A. Alisi, C. Della Corte, E. Fitzpatrick, M. Raponi, and A. Dhawan (2015). Nonalcoholic fatty liver disease: A challenge for pediatricians. JAMA Pediatr 169(2): 170-176.
98. Nobili, V., G. Bedogni, A. Alisi, A. Pietrobattista, A. Alterio, C. Tiribelli, and C. Agostoni (2009). A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. Arch Dis Child 94(10): 801-805.
99. Nobili, V., M. Marcellini, R. Devito, P. Ciampalini, F. Piemonte, D. Comparcola, M. R. Sartorelli, and P. Angulo (2006). NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice. Hepatology 44(2): 458-465.
100. Oh, S., T. Shida, K. Yamagishi, K. Tanaka, R. So, T. Tsujimoto, and J. Shoda (2015). Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: A retrospective study. Hepatology 61(4): 1205-1215.
101. Orci, L. A., K. Gariani, G. Oldani, V. Delaune, P. Morel, and C. Toso (2016). Exercise-based interventions for non-alcoholic fatty liver disease: A meta-analysis and meta-regression. Clin Gastroenterol Hepatol 14(10): 1398-1411.
102. Patel, A. and S. A. Harrison (2012). Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol Hepatol (N Y) 8(5): 305-312.
103. Perez-Guisado, J. and A. Munoz-Serrano (2011a). The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: A pilot study. J Med Food 14(7-8): 677-680.
104. Perez-Guisado, J. and A. Munoz-Serrano (2011b). A pilot study of the Spanish Ketogenic Mediterranean Diet: An effective therapy for the metabolic syndrome. J Med Food 14(7-8): 681-687.
105. Perez-Guisado, J., A. Munoz-Serrano, and A. Alonso-Moraga (2008). Spanish Ketogenic Mediterranean diet: A healthy cardiovascular diet for weight loss. Nutr J 7: 30.
106. Petersen, K. F., S. Dufour, D. Befroy, M. Lehrke, R. E. Hendler, and G. I. Shulman (2005). Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54(3): 603-608.
107. Petta, S., L. Miele, E. Bugianesi, C. Camma, C. Rosso, S. Boccia, D. Cabibi et al. (2014). Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One 9(2): e87523.
108. Pingitore, P., C. Pirazzi, R. M. Mancina, B. M. Motta, C. Indiveri, A. Pujia, T. Montalcini, K. Hedfalk, and S. Romeo (2014). Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta 1841(4): 574-580.
109. Porez, G., J. Prawitt, B. Gross, and B. Staels (2012). Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 53(9): 1723-1737.
110. Promrat, K., D. E. Kleiner, H. M. Niemeier, E. Jackvony, M. Kearns, J. R. Wands, J. L. Fava, and R. R. Wing (2010). Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51(1): 121-129.
111. Qi, J. C., J. C. Huang, Q. C. Lin, J. M. Zhao, X. Lin, L. D. Chen, J. F. Huang, and X. Chen (2015). Relationship between obstructive sleep apnea and nonalcoholic fatty liver disease in nonobese adults. Sleep Breath 20(2): 529-535.
112. Rakoski, M. O., A. G. Singal, M. A. Rogers, and H. Conjeevaram (2010). Meta-analysis: Insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 32(10): 1211-1221.
113. Reeder, S. B., I. Cruite, G. Hamilton, and C. B. Sirlin (2011). Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 34(4): 729-749.
114. Rinella, M. E. (2015). Nonalcoholic fatty liver disease: A systematic review. JAMA 313(22): 2263-2273.
115. Rofsky, N. M. and H. Fleishaker (1995). CT and MRI of diffuse liver disease. Semin Ultrasound CT MR 16(1): 16-33.
116. Romeo, S., J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, L. A. Pennacchio, E. Boerwinkle, J. C. Cohen, and H. H. Hobbs (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12): 1461-1465.
117. Rosqvist, F., D. Iggman, J. Kullberg, J. Cedernaes, H. E. Johansson, A. Larsson, L. Johansson et al. (2014). Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes 63(7): 2356-2368.
118. Rucker, D., R. Padwal, S. K. Li, C. Curioni, and D. C. Lau (2007). Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 335(7631): 1194-1199.
119. Ryan, M. C., F. Abbasi, C. Lamendola, S. Carter, and T. L. McLaughlin (2007). Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 30(5): 1075-1080.
120. Ryan, M. C., C. Itsiopoulos, T. Thodis, G. Ward, N. Trost, S. Hofferberth, K. O’Dea, P. V. Desmond, N. A. Johnson, and A. M. Wilson (2013). The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 59(1): 138-143.
121. Safadi, R., F. M. Konikoff, M. Mahamid, S. Zelber-Sagi, M. Halpern, T. Gilat, R. Oren, and FLORA Group (2014). The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12(12): 2085-2091 e2081.
122. Salomone, F., J. Godos, and S. Zelber-Sagi (2015). Natural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectives. Liver Int 36(1): 5-20.
123. Santoro, N., S. Caprio, B. Pierpont, M. Van Name, M. Savoye, and E. J. Parks (2015). Hepatic de novo lipogenesis in obese youth is modulated by a common variant in the GCKR gene. J Clin Endocrinol Metab 100(8): E1125-E1132.
124. Sanyal, A. J., N. Chalasani, K. V. Kowdley, A. McCullough, A. M. Diehl, N. M. Bass, B. A. Neuschwander-Tetri et al. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362(18): 1675-1685.
125. Satapathy, S. K., S. Garg, R. Chauhan, P. Sakhuja, V. Malhotra, B. C. Sharma, and S. K. Sarin (2004). Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99(10): 1946-1952.
126. Satapathy, S. K. and A. J. Sanyal (2015). Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 35(3): 221-235.
127. Satapati, S., B. Kucejova, J. A. Duarte, J. A. Fletcher, L. Reynolds, N. E. Sunny, T. He et al. (2016). Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J Clin Invest 126(4): 1605.
128. Schwarz, J. M., R. Chiolero, J. P. Revelly, C. Cayeux, P. Schneiter, E. Jequier, T. Chen, and L. Tappy (2000). Effects of enteral carbohydrates on de novo lipogenesis in critically ill patients. Am J Clin Nutr 72(4): 940-945.
129. Schwarz, J. M., P. Linfoot, D. Dare, and K. Aghajanian (2003). Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 77(1): 43-50.
130. Schwarz, J. M., K. Mulligan, J. Lee, J. C. Lo, M. Wen, M. A. Noor, C. Grunfeld, and M. Schambelan (2002). Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIVinfected patients with fat accumulation. J Clin Endocrinol Metab 87(2): 942.
131. Schwarz, J. M., S. M. Noworolski, M. J. Wen, A. Dyachenko, J. L. Prior, M. E. Weinberg, L. A. Herraiz et al. (2015). Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. J Clin Endocrinol Metab 100(6): 2434-2442.
132. Schwarz, J. M., S. M. Noworolski, A. Erkin-Cakmak, N. J., Korn, M. J. Wen, V. W. Tai, G. M. Jones et al. (2017). Effects of dietary fructose restriction on liver sat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology 153(3): 743-752.
133. Schwimmer, J. B., C. Behling, R. Newbury, R. Deutsch, C. Nievergelt, N. J. Schork, and J. E. Lavine (2005). Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 42(3): 641-649.
134. Sedlacek, S. M., M. C. Playdon, P. Wolfe, J. N. McGinley, M. R. Wisthoff, E. A. Daeninck, W. Jiang, Z. Zhu, and H. J. Thompson (2011). Effect of a low fat versus a low carbohydrate weight loss dietary intervention on biomarkers of long term survival in breast cancer patients (‘CHOICE’): Study protocol. BMC Cancer 11: 287.
135. Sert, A., O. Pirgon, E. Aypar, H. Yilmaz, and D. Odabas (2013). Subclinical hypothyroidism as a risk factor for the development of cardiovascular disease in obese adolescents with nonalcoholic fatty liver disease. Pediatr Cardiol 34(5): 1166-1174.
136. Siddiqui, M. S., M. Fuchs, M. O. Idowu, V. A. Luketic, S. Boyett, C. Sargeant, R. T. Stravitz et al. (2015). Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol 13(5): 1000-1008 e1003.
137. Singh, S. P., S. Nayak, M. Swain, N. Rout, R. N. Mallik, O. Agrawal, C. Meher, and M. Rao (2004). Prevalence of nonalcoholic fatty liver disease in coastal eastern India: A preliminary ultrasonographic survey. Trop Gastroenterol 25(2): 76-79.
138. Solhi, H., R. Ghahremani, A. M. Kazemifar, and Z. Hoseini Yazdi (2014). Silymarin in treatment of nonalcoholic steatohepatitis: A randomized clinical trial. Caspian J Intern Med 5(1): 9-12.
139. Speliotes, E. K., L. M. Yerges-Armstrong, J. Wu, R. Hernaez, L. J. Kim, C. D. Palmer, V. Gudnason et al. (2011). Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7(3): e1001324.
140. Spengler, E. K. and R. Loomba (2015). Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc 90(9): 1233-1246.
141. Tappy, L., M. Berger, J. M. Schwarz, M. McCamish, J. P. Revelly, P. Schneiter, E. Jequier, and R. Chiolero (1999). Hepatic and peripheral glucose metabolism in intensive care patients receiving continuous high-or low-carbohydrate enteral nutrition. JPEN J Parenter Enteral Nutr 23(5): 260-267; discussion 267-268.
142. Tappy, L., J. M. Schwarz, P. Schneiter, C. Cayeux, J. P. Revelly, C. K. Fagerquist, E. Jequier, and R. Chiolero (1998). Effects of isoenergetic glucose-based or lipid-based parenteral nutrition on glucose metabolism, de novo lipogenesis, and respiratory gas exchanges in critically ill patients. Crit Care Med 26(5): 860-867.
143. Targher, G., L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, C. Day, and G. Arcaro (2007). Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30(5): 1212-1218.
144. Taskinen, M. R. and J. Boren (2015). New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 239(2): 483-495.
145. Tay, J., N. D. Luscombe-Marsh, C. H. Thompson, M. Noakes, J. D. Buckley, G. A. Wittert, W. S. Yancy, Jr., and G. D. Brinkworth (2015). Response to comment on Tay et al. A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: A randomized trial. Diabetes Care 2014;37:2909-2918. Diabetes Care 38(4): e65-e66.
146. Tessari, P., A. Coracina, A. Cosma, and A. Tiengo (2009). Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 19(4): 291-302.
147. Thorburn, A. W., L. H. Storlien, A. B. Jenkins, S. Khouri, and E. W. Kraegen (1989). Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr 49(6): 1155-1163.
148. U.S. Department of Health and Human Services and U.S. Department of Agriculture December (2015). Dietary guidelines for Americans. 2015-2020. Retrieved December 2015, from http://health.gov/dietaryguidelines/2015/guidelines/.
149. Uygun, A., A. Kadayifci, A. T. Isik, T. Ozgurtas, S. Deveci, A. Tuzun, Z. Yesilova, M. Gulsen, and K. Dagalp (2004). Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19(5): 537-544.
150. Van Wagner, L. B., S. W. Koppe, E. M. Brunt, J. Gottstein, K. Gardikiotes, R. M. Green, and M. E. Rinella (2011). Pentoxifylline for the treatment of non-alcoholic steatohepatitis: A randomized controlled trial. Ann Hepatol 10(3): 277-286.
151. Vassilatou, E., D. A. Vassiliadi, K. Salambasis, H. Lazaridou, N. Koutsomitopoulos, N. Kelekis, D. Kassanos, D. J. Hadjidakis, and G. Dimitriadis (2015). Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease. Eur J Endocrinol 173(6): 739-747.
152. Volynets, V., J. Machann, M. A. Kuper, I. B. Maier, A. Spruss, A. Konigsrainer, S. C. Bischoff, and I. Bergheim (2013). A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): A pilot study. Eur J Nutr 52(2): 527-535.
153. Wong, V. W., W. C. Chu, G. L. Wong, R. S. Chan, A. M. Chim, A. Ong, D. K. Yeung et al. (2012). Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61(3): 409-415.
154. Wu, J. H., R. N. Lemaitre, A. Manichaikul, W. Guan, T. Tanaka, M. Foy, E. K. Kabagambe et al. (2013). Genome-wide association study identifies novel loci associated with concentrations of four plasma phospholipid fatty acids in the de novo lipogenesis pathway: Results from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 6(2): 171-183.
155. Yamamoto, K., Y. Takada, Y. Fujimoto, H. Haga, F. Oike, N. Kobayashi, and K. Tanaka (2007). Nonalcoholic steatohepatitis in donors for living donor liver transplantation. Transplantation 83(3): 257-262.
156. Zein, C. O., L. M. Yerian, P. Gogate, R. Lopez, J. P. Kirwan, A. E. Feldstein, and A. J. McCullough (2011). Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology 54(5): 1610-1619.
157. Zeng, T., C. L. Zhang, X. L. Zhao, and K. Q. Xie (2014). Pentoxifylline for the treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized double-blind, placebo-controlled studies. Eur J Gastroenterol Hepatol 26(6): 646-653.
158. Zhu, J. Z., Y. N. Dai, Y. M. Wang, Q. Y. Zhou, C. H. Yu, and Y. M. Li (2015). Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Dig Dis Sci 60(11): 3194-3202.